Literature DB >> 8585755

Susceptibility testing with clavulanic acid: fixed concentration versus fixed ratio.

C J Thomson, R S Miles, S G Amyes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8585755      PMCID： PMC162994          DOI： 10.1128/AAC.39.11.2591

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  7 in total

1.  Occurrence and detection of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae at a veterans medical center: seek and you may find.

Authors:  P E Coudron; E S Moland; C C Sanders
Journal:  J Clin Microbiol       Date:  1997-10       Impact factor: 5.948

2.  Which antibiotics and breakpoints should be used for Aeromonas susceptibility testing? Considerations from a comparison of agar dilution and disk diffusion methods using Enterobacteriaceae breakpoints.

Authors:  B Lamy; F Laurent; A Kodjo; F Roger; E Jumas-Bilak; H Marchandin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-02-27       Impact factor: 3.267

3.  Effects of following National Committee for Clinical Laboratory Standards and Deutsche Industrie Norm-Medizinische Mikrobiologie guidelines, country of isolate origin, and site of infection on susceptibility of Escherichia coli to amoxicillin-clavulanate (Augmentin).

Authors:  I Simpson; J Durodie; S Knott; B Shea; J Wilson; K Machka
Journal:  J Clin Microbiol       Date:  1998-05       Impact factor: 5.948

4.  In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains.

Authors:  Paul G Higgins; Hilmar Wisplinghoff; Danuta Stefanik; Harald Seifert
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

Review 5.  Three decades of beta-lactamase inhibitors.

Authors:  Sarah M Drawz; Robert A Bonomo
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

Review 6.  What the Clinical Microbiologist Should Know About Pharmacokinetics/Pharmacodynamics in the Era of Emerging Multidrug Resistance: Focusing on β-Lactam/β-Lactamase Inhibitor Combinations.

Authors:  Henrietta Abodakpi; Audrey Wanger; Vincent H Tam
Journal:  Clin Lab Med       Date:  2019-07-06       Impact factor: 1.935

7.  Ampicillin-sulbactam and amoxicillin-clavulanate susceptibility testing of Escherichia coli isolates with different beta-lactam resistance phenotypes.

Authors:  A Oliver; M Pérez-Vázquez; M Martínez-Ferrer; F Baquero; L De Rafael; R Cantón
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.